knowledge

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

advertisement

Featured Speakers

• Irena Melnikova, Ph.D., partner, Pfizer Ventures
• Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
• Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.